For the Inventor, By the Inventor

Enter assignee name

Fort Worth, TX, United States of America

Nacuity Pharmaceuticals, Inc.

Calculating rank

USPTO Granted Patents = 11

CIPO Patents = 1

EPO Patents = 2

Trademarks = 2

Forward Citations = 24

Loading Chart...

Loading Chart...

15 inventors (with patents filed for the assignee):

G Michael Wall (8 out of 15 patents)

Anja Rubenstein (3 out of 4 patents)

Rodney Tucker (3 out of 4 patents)

4. Josh Bolger (3 out of 4 patents)

5. Doug Johnson (2 out of 3 patents)

6. Sambaiah Thota (2 out of 3 patents)

7. John W Lee (2 out of 3 patents)

8. Srinavasa Cheruku (2 out of 2 patents)

9. John Charles Warner (2 out of 49 patents)

10. Douglas Giles Johnson (1 out of 6 patents)

11. Peter Anthony Campochiaro (1 out of 26 patents)

12. Marcin Jakub Kowalczyk (1 out of 1 patent)

13. Craig Sheehan (1 out of 1 patent)

14. Daniel Hartman (1 out of 1 patent)

15. Jami Kern (1 out of 1 patent)

11 patents: Sort by Forward Citations

1. 12667548 - Treatment of retinitis pigmentosa and retinitis pigmentosa associated with Usher Syndrome with N-acetylcysteine amide (2026-06-30),

2. 12662449 - Method for preparation of N-acetyl cysteine amide and derivatives thereof (2026-06-23),

3. 12472157 - Treatment of retinitis pigmentosa with n-acetylcysteine amide (2025-11-18),

4. 12458608 - N-Acetylcysteine Amide (NACA) and (2R,2R')-3,3′ disulfanediyl BIS(2-acetamidopropanamide) (DINACA) for the prevention and treatment of radiation dermatitis and skin lightening, skin whitening and skin improvement (2025-11-04),

5. 12245998 - N-acetylcysteine amide (NACA) and (2R,2R')-3,3′ disulfanediyl bis(2-acetamidopropanamide) (diNACA) for the prevention and treatment of radiation pneumonitis and treatment of pulmonary function in Cystic Fibrosis (2025-03-11),

6. 11766413 - Treatment of age-related macular degeneration, glaucoma, and diabetic retinopathy with n-acetylcysteine amide (NACA) or (2R,2R')-3,3′-disulfanediyl BIS(2-acetamidopropanamide)(DiNACA) (2023-09-26),

7. 11753370 - Methods of making deuterium-enriched N-acetylcysteine amide (d-NACA) and (2R, 2R')-3,3′-disulfanediyl bis(2-acetamidopropanamide) (diNACA) and using d-NACA and diNACA to treat diseases involving oxidative stress (2023-09-12),

8. 11548851 - Method for preparation of n-acetyl cysteine amide and derivatives thereof (2023-01-10),

9. 10590073 - Method for preparation of N-acetyl cysteine amide and derivatives thereof (2020-03-17),

10. 9889103 - Method for the preparation of N-acetyl cysteine amide (2018-02-13),

11. 9763902 - Method for preparation of N-acetyl cysteine amide (2017-09-19),

Company Overview

Nacuity Pharmaceuticals, Inc. is a biotechnology company based in Fort Worth, Texas, focused on developing innovative therapies for ocular diseases. The company specializes in advancing treatments that address unmet medical needs in the field of ophthalmology, leveraging proprietary technologies to enhance drug delivery and efficacy. Nacuity's research efforts are dedicated to improving patient outcomes through the development of novel pharmacological solutions, aiming to transform the landscape of eye care.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

11 Patents

#78 in Fort Worth, TX

#1,726 in Texas

#27,529 in US

#51,801 in the World

Fort Worth, TX, United States of America

Nacuity Pharmaceuticals, Inc.

Forward Citations = 24

15 inventors:

G Michael Wall (8 out of 15 patents)

Anja Rubenstein (3 out of 4 patents)

Rodney Tucker (3 out of 4 patents)

4. Josh Bolger (3 out of 4 patents)

5. Doug Johnson (2 out of 3 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Nacuity Pharmaceuticals, Inc.. Retrieved from https://idiyas.com/company/nacuity-pharmaceuticals

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…